{"id":"NCT00089674","sponsor":"Amgen","briefTitle":"AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-08-01","primaryCompletion":"2008-05-16","completion":"2010-05-11","firstPosted":"2004-08-11","resultsPosted":"2014-06-03","lastUpdate":"2018-10-17"},"enrollment":1468,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"AMG 162","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"AMG 162","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.","primaryOutcome":{"measure":"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24","timeFrame":"24 months","effectByArm":[{"arm":"Placebo","deltaMin":-1,"sd":null},{"arm":"Denosumab 60 mg Q6M","deltaMin":5.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["22641239","19671656","21898590","19836774","21555773"],"seeAlso":["http://www.amgentrials.com","http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":222,"n":725},"commonTop":["Arthralgia","Back pain","Constipation","Pain in extremity","Hypertension"]}}